July 2016

New Product - Praxbind

Praxbind (idarucizumab, rch) is a humanised monoclonal antibody fragment (Fab) molecule derived from murine IgG1 isotype antibody molecule. It binds to dabigatran with very high affinity, approximately 300‑fold higher than the binding affinity of dabigatran for thrombin at physiological pH (pH 7.4). Idarucizumab specifically binds to dabigatran and its acyl glucuronide metabolites and potently neutralises their anticoagulant effect. Idarucizumab is a specific reversal agent for dabigatran. Praxbind is indicated in patients treated with dabigatran etexilate (Pradaxa) when rapid reversal of the anticoagulant effects of dabigatran is required for emergency surgery/urgent procedures and in life‑threatening or uncontrolled bleeding. Praxbind is available as a 50 mg/mL solution for injection/infusion in a 50 ml glass vial in packs of 2’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629